Anthelmintic Drugs: Tools and Shortcuts for the Long Road from Discovery to Product

Parasitic Helminths: Targets, Screens, Drugs and Vaccines

Volumn , Issue , 2012, Pages 217-232

  de Hostos, Eugenio L ^a   Nguyen, Tue ^a  

^a Institute of OneWorldHealth   (United States)

Author keywords

Anthelmintic drug; Clinical trial; Drug development; Neglected tropical disease; Product development partnership; Target product profile

Indexed keywords

EID: 84886118451     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527652969.ch13     Document Type: Chapter

References (36)

1. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., and Ford, N. (2002) Drug development for neglected diseases: a deficient market and a publichealth policy failure. Lancet, 359, 2188-2194.
2. Pink, R.,Hudson, A., Mouriès, M.-A., and Bendig, M. (2005) Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug. Discov., 4, 727-740.
3. Stoll, N.R. (1962) On endemic hookworm, where do we stand today? Exp. Parasitol., 12, 241-252.
4. Bethony, J., Brooker, S., Albonico, M., Geiger, S.M., Loukas, A., Diemert, D., and Hotez, P.J. (2006) Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet, 367, 1521-1532.
5. Hotez, P.J. (2010) How to cure 1 billion people? Defeat neglected tropical diseases. Sci. Am., 302, 90-94.
6. Bleakly, H. (2007) Disease and development: evidence from hookworm eradication in the American South. Q. J. Econ., 122, 73-117.
7. Boccaccio, M. (1972) Ground Itch and Dew poison the Rockefeller Sanitary Commission 1909-14. J. Hist. Med. Allied Sci., XXVII, 30-53.
8. Hotez, P.J., Brindley, P.J., Bethony, J.M., King, C.H., Pearce, E.J., and Jacobson, J. (2008) Helminth infections: the great neglected tropical diseases. J. Clin. Invest., 118, 1311-1321.
9. Hotez, P.J., Bundy, D.A.P., Beegle, K., Brooker, S., Drake, L., de Silva, N., Montresor, A. et al. (2006) Helminth infections: soil-transmitted helminth infections and schistosomiasis, in Disease Control Priorities in Developing Countries (eds D.T. Jamison, J.G. Breman, A.R. Measham, and G. Alleyne), World Bank Publications, Washington, DC, pp. 467-482.
10. Keiser, J. and Utzinger, J. (2010) The drugs we have and the drugs we need against major helminth infections. Adv. Parasitol., 73, 197-230.
11. Olliaro, P., Seiler, J., Kuesel, A., Horton, J., Clark, J.N., Don, R., and Keiser, J. (2011) Potential drug development candidates for human soil-transmitted helminthiases. PLoS Negl. Trop. Dis., 5, e1138.
12. Keiser, J. and Utzinger, J. (2008) Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. J. Am.Med. Assoc., 299, 1937-1948.
13. Katiyar, D. and Singh, L.K. (2011) Filariasis: current status, treatment and recent advances in drug development. Curr. Med. Chem., 18, 2174-2185.
14. Boutayeb, A. (2007) Developing countries and neglected diseases: challenges and perspectives. Int. J. Equity Health, 6, 20.
15. Keiser, J., Ingram, K., and Utzinger, J. (2011) Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control. Parasitology, 138, 1620-1632.
16. Sangster, N. (1999) Pharmacology of anthelmintic resistance. Parasitol. Today, 15, 141-146.
17. Kaplan, R.M. (2004) Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol., 20, 477-481.
18. Albonico, M., Bickle, Q., Ramsan, M., Montresor, A., Savioli, L., and Taylor, M. (2003) Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull. World Health Organ., 81, 343-352.
19. Flohr, C., Tuyen, L.N., Lewis, S., Minh, T.T., Campbell, J., Britton, J., Williams, H. et al. (2007) Low efficacy of mebendazole against hookworm in Vietnam: two randomized controlled trials. Am. J. Trop. Med. Hyg., 76, 732-736.
20. De Clercq, D., Sacko, M., Behnke, J., Gilbert, F., Dorny, P., and Vercruysse, J. (1997) Failure of mebendazole in treatment of human hookworminfections in the southern region ofMali. Am. J. Trop. Med. Hyg., 57, 25-30.
21. Geerts, S. and Gryseels, B. (2000) Drug resistance in human helminths: current situation and lessons from livestock. Clin. Microbiol. Rev., 13, 207-222.
22. Kaminsky, R. (2003) Drug resistance in nematodes: a paper tiger or a real problem? Curr. Opin. Infect. Dis., 16, 559-564.
23. Prichard, R.K. and Geary, T.G. (2008) Drug discovery: fresh hope to can the worms. Nature, 452, 157-158.
24. Kaminsky, R., Ducray, P., Jung, M., Clover, R., Rufener, L., Bouvier, J., Weber, S.S. et al. (2008) A new class of anthelmintics effective against drugresistant nematodes. Nature, 452, 176-180.
25. Welz, C., Krüger, N., Schniederjans, M., Miltsch, S.M., Krücken, J., Guest, M., Holden-Dye, L. et al. (2011) SLO-1 channels of parasitic nematodes reconstitute locomotor behaviour and emodepside sensitivity in Caenorhabditis elegans slo-1 loss of function mutants. PLoS Pathog., 7, e1001330.
26. Mackenzie, C.D. and Geary, T.G. (2011) Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev. Anti Infect. Ther., 9, 497-501.
27. Brown, D. and Superti-Furga, G. (2003) Rediscovering the sweet spot in drug discovery. Drug Discov. Today, 8, 1067-1077.
28. Gut, J., Ang, K.K.H., Legac, J., Arkin, M.R., Rosenthal, P.J., andMcKerrow, J.H. (2011) An image-based assay for high throughput screening of Giardia lamblia. J. Microbiol. Methods, 84, 398-405.
29. Caffrey, C.R., Steverding, D., Swenerton, R.K., Kelly, B., Walshe, D., Debnath, A., Zhou, Y.-M. et al. (2007) Bisacridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro. Antimicrob. Agents Chemother., 51, 2164-2172.
30. Abdulla, M.H., Ruelas, D.S., Wolff, B., Snedecor, J., Lim, K.C., Xu, F., Renslo, A.R. et al. (2009) Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis., 3, e478.
31. Mansour, N.R. and Bickle, Q.D. (2010) Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl. Trop. Dis., 4, e795.
32. Hotez, P.J., Bethony, J.M., Diemert, D.J., Pearson, M., and Loukas, A. (2010) Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol., 8, 814-826.
33. Moran, M., Strub-Wourgaft, N., Guzman, J., Boulet, P., Wu, L., and Pecoul, B. (2011) Registering new drugs for low-income countries: the African challenge. PLoS Med., 8, e1000411.
34. Nwaka, S., Ramirez, B., Brun, R.,Maes, L., Douglas, F., and Ridley, R. (2009) Advancing drug innovation for neglected diseases - criteria for lead progression. PLoS Negl. Trop. Dis., 3, e440.
35. Moran, M. (2005) A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med., 2, e302.
36. Nwaka, S. and Ridley, R.G. (2003) Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov., 2, 919-928.